WO2026083296 - TRISPECIFIC COMPOSITIONS COMPRISING IL-18, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS

National phase entry is expected:
Publication Number WO/2026/083296
Publication Date 23.04.2026
International Application No. PCT/IB2025/060509
International Filing Date 15.10.2025
Title **
[English] TRISPECIFIC COMPOSITIONS COMPRISING IL-18, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS
[French] COMPOSITIONS TRISPÉCIFIQUES COMPRENANT IL-18, DOMAINES DE LIAISON AU VEGF ET DOMAINES DE LIAISON À PD-1
Applicants **
BRIGHT PEAK THERAPEUTICS AG
Inventors
PATTABIRAMAN, Vijaya Raghavan
KREFT, Bertolt
GOEPFERT, Arnaud
MARTIN, Kea
BORNERT, Olivier
RESCHKE, Nina
Priority Data
63/708,087   16.10.2024   US
63/739,331   27.12.2024   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting8154
EPO Filing, Examination, Granting179910
Japan Filing, Examination, Granting5266
South Korea Filing, Examination, Granting12135
USA Filing, Examination, Granting36390
MasterCard Visa
Total: 241,855
Contact Us
Abstract[English] The present disclosure relates anti-PD-1/anti-VEGF immunocytokines, particularly with IL-18. Also described herein are new formats of bispecific anti-PD-1 and anti-VEGF constructs. Further described herein are IL-18 / anti-VEGF immunocytokines. Also provided herein are pharmaceutical composition and methods of treatment using the same.[French] La présente divulgation concerne des immunocytokines anti-PD-1/anti-VEGF, en particulier avec IL-18. L'invention concerne également de nouveaux formats de constructions anti-PD-1 et anti-VEGF bispécifiques. L'invention concerne en outre des immunocytokines IL-18/anti-VEGF. L'invention concerne également une composition pharmaceutique et des méthodes de traitement les utilisant.